儿童重症社区获得性肺炎的诊断与预测前景:分子生物学技术及生物标志物  

Diagnosis and Prediction of Severe Community-Acquired Pneumonia in Children:Molecular Biological Techniques and Biomarkers

作　　者：马冉 刘思媛 张丽[2] 袁博[2] 章伟 Ma Ran;Liu Siyuan;Zhang Li(Shihezi University School of Medicine,Shihezi,Xinjiang,832002,China)

机构地区：[1]石河子大学医学院,新疆石河子832002 [2]石河子大学第一附属医院儿科,新疆石河子832008

出　　处：《黑龙江医学》2025年第5期632-634,共3页Heilongjiang Medical Journal

基　　金：兵团指导性科技计划项目(2022ZD031);八师石河子市财政科技计划项目(2022NY01);石河子大学科研项目(ZZZC202072A)。

摘　　要：儿童重症社区获得性肺炎病死率较高,起病急骤,病情进展迅速,未明确病原阻碍精准治疗,使病情延误,对患儿身心健康造成严重危害。新型分子生物学诊断技术及生物标志物有助于早期识别病原、预测重症风险、尽早干预,从而改善重症肺炎病情,减少并发症的产生。文章综述了病原诊断分子生物学技术及和评估预后的生物标志物,旨在指导儿童重症肺炎的诊疗、风险预警、疾病转归。Severe community-acquired pneumonia(SCAP)is a severe respiratory disease involving multiple organ damage.It has a high fatality rate.SCAP develops and progresses rapidly in children.A lack of pathogenic diagnosis may hinder targeted treatment,prolong illness,and pose inestimable physical and psychological consequences in children.The novel molecular biological diagnostic technology and biomarkers can help to identify the pathogen early,predict the risk of severe pneumonia,and intervene early,so as to improve the condition of severe pneumonia and reduce the occurrence of complications.The study reviews molecular biological techniques for pathogen diagnosis and biomarkers for prognosis assessment,so as to to guide diagnosis and treatment,risk warning and disease outcome of severe pneumonia in children.

关 键 词：儿童 重症社区获得性肺炎 分子生物学诊断 生物标志物 

分 类 号：R725.6[医药卫生—儿科]